Clinical Trial: Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.
Brief Summary: The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to Calcitonin Gene Related Peptide (CGRP)infusion.
Detailed Summary:
Calcitonin Gene Related Peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in approximately 50% of migraine sufferers. Treatment of spontaneous migraine attacks with an antagonist to CGRP is effective in many patients. These data show that CGRP is involved in both initiation and maintenance of migraine attack.
The consequence of migraine gene mutations on relevant migraine pathways has never been tested. The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to CGRP infusion. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.
Sponsor: Danish Headache Center
Current Primary Outcome:
- headache and associated symptoms
- blood flow velocity of the middle cerebral artery
- diameter of the superficial temporal artery
Original Primary Outcome: Same as current
Current Secondary Outcome:
- MAP
- HR
Original Secondary Outcome: Same as current
Information By: Danish Headache Center
Dates:
Date Received: July 31, 2006
Date Started: July 2006
Date Completion: October 2006
Last Updated: November 9, 2006
Last Verified: November 2006